9D9-CP006單克隆抗體是原始9D9單克隆抗體的重組嵌合型抗體。可變結構域序列與原始9D9克隆號相同，但是恒定區序列已經從小鼠IgG2b變為小鼠IgG1。9D9-CP006單克隆抗體能與小鼠CTLA-4(細胞毒性T淋巴細胞抗原-4)反應，CTLA-4也稱為CD152。CTLA-4是一種33 kDa的細胞表面受體，由屬于免疫球蛋白超家族CD28家族的Ctla4基因編碼。CTLA-4在活化的T淋巴細胞和B淋巴細胞上表達。CTLA-4在結構上類似于T細胞共刺激蛋白CD28，兩種分子都與B7家族成員B7-1 (CD80)和B7-2 (CD86)結合。在與配體結合時，CTLA-4負調節細胞介導的免疫反應。CTLA-4在誘導和/或維持免疫耐受、胸腺細胞發育和保護性免疫調節中起作用。CTLA-4在免疫下調中的關鍵作用已經在CTLA-4缺陷小鼠中得到證實，這些小鼠在3-5周齡時由于淋巴增生性疾病的發展而死亡。CTLA-4是目前腫瘤免疫檢查點治療的熱門靶點之一。
產品詳情：
|
產品名稱 |
RecombiMAb anti-mouse CTLA-4 (CD152) |
|
產品貨號 |
CP006 |
|
產品規格 |
1mg |
|
反應種屬 |
Mouse |
|
克隆號 |
9D9-CP006 |
|
同種型 |
Mouse IgG1(switched from mouse IgG2b) |
|
免疫原 |
Not available or unknown |
|
實驗應用 |
in vivo CTLA-4 neutralization* Western blot* *Reported for the original mouse IgG2b 9D9 antibody |
|
產品形式 |
PBS, pH 7.0,Contains no stabilizers or preservatives |
|
純度 |
>95%, Determined by SDS-PAGE |
|
聚合 |
<5%, Determined by SEC |
|
無菌處理 |
0.2 µm filtration |
|
純化方式 |
Protein G |
|
分子量 |
150 kDa |
|
小鼠病原檢測 |
Ectromelia/Mousepox Virus: Negative Hantavirus: Negative K Virus: Negative Lactate Dehydrogenase-Elevating Virus: Negative Lymphocytic Choriomeningitis virus: Negative Mouse Adenovirus: Negative Mouse Cytomegalovirus: Negative Mouse Hepatitis Virus: Negative Mouse Minute Virus: Negative Mouse Norovirus: Negative Mouse Parvovirus: Negative Mouse Rotavirus: Negative Mycoplasma Pulmonis: Negative Pneumonia Virus of Mice: Negative Polyoma Virus: Negative Reovirus Screen: Negative Sendai Virus: Negative Theiler’s Murine Encephalomyelitis: Negative |
|
保存條件 |
抗體原液保存在4°C，不能冷凍保存。 |
|
推薦同型對照 |
InVivoPlus mouse IgG1 isotype control, unknown specificity（貨號BP0083） |
|
推薦抗體稀釋液 |
InVivoPure pH 7.0 Dilution Buffer（貨號IP0070） |
該產品自上市已被多篇SCI文獻引用，品質有保證，以下是部分已發表的文獻引用：
|
應用 |
文章 |
|
體內CTLA-4中和 (in vivo CTLA-4 neutralization) |
1. Dai, M., et al. (2015). 'Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies' Clin Cancer Res 21(5): 1127-1138. 2. Zippelius, A., et al. (2015). 'Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment' Cancer Immunol Res 3(3): 236-244. 3. Redmond, W. L., et al. (2014). 'Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity' Cancer Immunol Res 2(2): 142-153. 4. Condamine, T., et al. (2014). 'ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis' J Clin Invest 124(6): 2626-2639. 5. Muller, P., et al. (2014). 'Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells' Cancer Immunol Res 2(8): 741-755. 6. Bulliard, Y., et al. (2013). 'Activating Fc gamma receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies' J Exp Med 210(9): 1685-1693. |
更多產品詳情請咨詢 BioXCell 中國授權代理——欣博盛生物
全國服務熱線: 4006-800-892 郵箱: market@neobioscience.com
深圳: 0755-26755892 北京: 010-88594029
廣州：020-87615159 上海: 021-34613729
代理品牌網站: www.neobioscience.com
自主品牌網站: www.neobioscience.net